Human low-density lipoprotein receptor plays an important role in hepatitis B virus infection

Hepatitis B virus (HBV) chronically infects more than 240 million people worldwide, resulting in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HBV vaccine is effective to prevent new HBV infection but does not offer therapeutic benefit to hepatitis B patients. Neither are current antiviral drugs curative of chronic hepatitis B. A more thorough understanding of HBV infection and replication holds a great promise for identification of novel antiviral drugs and design of optimal strategies towards the ultimate elimination of chronic hepatitis B. Recently, we have developed a robust HBV cell culture system and discovered that human apolipoprotein E (apoE) is enriched on the HBV envelope and promotes HBV infection and production. In the present study, we have determined the role of the low-density lipoprotein receptor (LDLR) in HBV infection. A LDLR-blocking monoclonal antibody potently inhibited HBV infection in HepG2 cells expressing the sodium taurocholate cotransporting polypeptide (NTCP) as well as in primary human hepatocytes. More importantly, small interfering RNAs (siRNAs)-mediated knockdown of LDLR expression and the CRISPR/Cas9-induced knockout of the LDLR gene markedly reduced HBV infection. A recombinant LDLR protein could block heparin-mediated apoE pulldown, suggesting that LDLR may act as an HBV cell attachment receptor via binding to the HBV-associated apoE. Collectively, these findings demonstrate that LDLR plays an important role in HBV infection probably by serving as a virus attachment receptor.

infection and production. Interestingly, apoE was previously found to also play a critical role in hepatitis C virus (HCV) cell attachment and morphogenesis via binding to hepatocyte surface receptors heparan sulfate proteoglycans (HSPGs) and viral proteins NS5A and E1/E2, respectively, as demonstrated by several independent studies [23][24][25]. ApoE is known to play a central role in the transport, metabolism, and homeostasis of cholesterol and apoE-containing lipoproteins by serving as a critical ligand for the low-density lipoprotein receptor (LDLR) [26][27][28]. Therefore, we believe that apoE promotes HBV infection through binding to cell surface receptors such as LDLR and HSPGs.
HSPGs are implicated in HBV cell attachment, as suggested by previous studies [29,30]. Removal of HSPGs from cell surface by treatment of cells with heparinase conferred less susceptibility to HBV infection [29]. Similarly, heparin was shown to block HBV infection in cell culture [30]. One of the HSPG core proteins, glypican 5 (GPC5), was found to be an HBV entry factor [31,32]. These previous studies suggest that HSPGs likely serve as HBV attachment receptors. However, the role of LDLR in HBV infection has not been experimentally examined. In the present study, we sought to determine the role of LDLR in HBV infection. Strikingly, a LDLRspecific monoclonal antibody (C7) potently blocked HBV infection in the NTCP-expressing HepG2 cell line and primary human hepatocytes (PHHs). Likewise, silencing of LDLR expression and the CRISPR/Cas9-induced knockout of the LDLR gene efficiently lowered HBV infection but did not affect HBV DNA replication. Interestingly, a recombinant LDLR protein was able to block apoE pull-down. Collectively, these findings suggest that LDLR promotes HBV infection probably through its interaction with apoE enriched on the HBV envelope.

Efficient blockade of HBV infection by a LDLR-specific monoclonal antibody
We have previously found that human apoE is enriched in HBV envelope and plays an important role in HBV infection although its mechanism of action has not been defined [22]. It is known that both HSPGs and LDLR family proteins serve as the apoE-binding receptors [28]. HSPGs was previously found to facilitate both HBV and HCV cell attachment [24,29,30,[33][34][35]. To determine whether LDLR plays a role in HBV infection, we initially tested a LDLRblocking monoclonal antibody (C7) using our previously described HepG2 NTCP cell culture model of HBV infection [17]. HepG2 NTCP cells were efficiently infected with HBV, as demonstrated by increasing levels of HBcAg expression up to 5 days after infection, which were determined by both Western blot analysis (S1A Fig) and IFA (S1B Fig). Thus, this robust HBV cell culture model was used in this study. HBV was mixed with varying amounts (0, 0.4, 2, and 10 μg/mL) of C7 prior to its infection of HepG2 NTCP cells. The effect of C7 on HBV infection was subsequently determined by quantifying the levels of HBV DNAs and proteins in the cell and cell culture supernatant. The LDLR-specific monoclonal antibody C7 was found to potently block HBV infection, as determined by dose-dependent reduction of HBcAg and HBV cccDNA in cells as well as HBeAg and HBV DNA in supernatants (Fig 1). The levels of HBcAg, HBV cccDNA, and HBeAg were lowered by about 60% at a concentration of 10 μg/ mL of C7 compared to no antibody control or 10 μg/mL of a normal mouse IgG (nmIgG) ( Fig  1A, 1B, and 1C). The level of HBV DNA in the supernatant was 5-folds lower in the presence of 10 μg/mL of C7 compared to the control without C7 or 10 μg/mL of nmIgG ( Fig 1D). To determine the physiological importance of LDLR in HBV infection, we used primary human hepatocytes (PHHs) for HBV infection. HBV was incubated with increasing amounts (0, 0.4, 2, and 10 μg/mL) of C7 during infection. Again, C7 efficiently blocked HBV infection in PHHs, resulting in 57%, 70%, and 88% reduction of HBcAg in the cell at concentrations of 0.4, 2, and 10 μg/mL of C7 (Fig 2A). The level of HBeAg in the supernatants were also HepG2 NTCP cells seeded in 24-well plates were infected with HBV in the presence of 4% PEG and increasing concentrations (0, 0.4, 2, and 10 μg/mL) of the LDLR monoclonal antibody (C7). A normal mouse IgG (nmIgG) was used as a negative control. After 12-h infection at 37˚C, the HBV-infected cells were washed with PBS and incubated with DME/F12 containing 3% FBS, 1% DMSO, 5 μg/mL hydrocortisone (HC), and corresponding concentrations of C7 or nmIgG for 4 days. Cell lysates were collected for detection of HBV core antigen (HBcAg) by Western blot using β-actin as a house-keeping gene control (A). HBV cccDNA in the cells was extracted with the Hirt method and treated with exonucleases I, III, and T5, as previously described [22]. The levels of HBV cccDNA were determined by a Real-Time PCR method (B). The levels of HBeAg in the supernatants were quantified by the previously described chemiluminescence immunoassay (C). The levels of HBV genomic DNA in the supernatants were also quantified by a Real-Time PCR method (D). The average levels of HBV cccDNA, HBeAg, and HBV DNA were obtained from three independent experiments and plotted against C7 concentrations. � P < 0.05, �� P < 0.01, ��� P < 0.001. https://doi.org/10.1371/journal.ppat.1009722.g001

Fig 2. C7 neutralization of HBV infectivity in PHH.
PHHs seeded in a 24-well plate were infected with HBV in the presence of 4% PEG and increasing concentrations (0, 0.4, 2, and 10 μg/mL) of C7 using nmIgG (10 μg/mL) as a negative control. After 12-hrs incubation at 37˚C, the HBV-infected PHHs were washed with PBS and incubated in Power primary HEP medium with the corresponding concentrations of C7 or nmIgG used during HBV infection. At 4-days post-infection (p.i.), cells were lysed with RIPA buffer. The levels of HBcAg were determined by Western blot analysis (A). The levels of HBeAg in the supernatants were quantified by a chemiluminescence immunoassay (B). Average levels of HBeAg in the supernatants obtained from triplicate repeats were calculated and plotted against the concentrations of C7. �� P < 0.01, ��� P < 0.001. proportionally decreased by up to greater than 50% ( Fig 2B). The blockade of HBV infection by C7 was also determined when added during or after HBV infection (Fig 3). C7 blocked HBV infection only when added during infection, resulting in proportional reduction of HBcAg by up to 65% (Fig 3A). However, the levels of HBcAg remained unchanged when C7 was added after HBV infection ( Fig 3B). HepG2 NTCP cells do not support HBV propagation, which explains why C7 did not affect the levels of HBcAg when added after HBV infection. Taken together, these results suggest that LDLR plays an important role in HBV infection.

Impairment of HBV infection by down-regulation of LDLR expression
To further validate the importance of LDLR in HBV infection, we have determined the effects of down-regulation of LDLR expression on HBV infection. Initially, a smartpool of LDLR-specific siRNAs (siLDLR) was used to silence LDLR expression in HepG2 NTCP cells, followed by HBV infection. A non-specific control siRNA (siNSC) was included in the experiments. Unlike siNSC, siLDLR was able to reduce LDLR expression in a dose-dependent manner to an undetectable level at 50 nM as shown by Western blot analysis ( Fig 4A). As a result, the levels of HBcAg in the HBV-infected HepG2 NTCP cells were proportionally decreased by 15%, 48% and 74% at 2, 10, and 50 nM of siRNAs ( Fig 4A). Similarly, the level of HBV cccDNA were lowered by 40%, 80%, and 85% at 2 nM, 10 nM and 50 nM of LDLR-specific siRNAs ( Fig 4B). HBeAg and HBV DNA in the cell culture supernatants were reduced by greater than 80% at 50 nM siLDLR concentration compared to those in the siNSC-transfected cells (Fig 4C and 4D). The reduction of HBV infection by silencing LDLR expression was also confirmed by HBcAg immunostaining of HBV-infected cells (S2 Fig). These results demonstrate that LDLR is required for efficient HBV infection.
To further verify the importance of LDLR in HBV infection, we used the CRISPR/Cas9 technology to make stable LDLR gene-knockout (LDLR -/-) HepG2 NTCP cell lines. Upon selection with blasticidin, we have obtained a number of cell clones. Three independent clones were chosen for the subsequent experiments, which contain 20, 7, and 10 nucleotide deletions around the sgRNA targeting region, respectively, as determined by DNA sequence analysis ( Fig 5A). As expected, LDLR was undetectable among these stable LDLR -/-HepG2 NTCP cell lines, as shown by Western blot analysis (Fig 5A). The susceptibility of these LDLR -/cell lines was determined by an HBV infection assay. Strikingly, LDLR gene knockout resulted in 80% to 90% reduction of HBcAg and HBV cccDNA in the HBV-infected cells (Fig 5A and 5B). HBeAg and HBV DNA in LDLR -/-HepG2 NTCP cell culture supernatants were greater than 85% lower than those in the parental (w.t.) cells (Fig 5C and 5D). These results confirm that LDLR plays an important role in HBV infection.

Fig 4. Reduction of HBV infection by LDLR-specific siRNAs.
HepG2 NTCP cells were transfected with a Smartpool of LDLR-specific siRNAs at varying concentrations (0, 2, 10, 50 nM) using RNAiMax (Invitrogen) as described in our previous work [22]. A non-specific control siRNA (siNSC) was used as a control. At 2-days post-transfection (p.t.), cells were infected with HBV in the presence of 4% PEG at 37˚C for 12 hrs. At 4-days p.i., the levels of LDLR and HBcAg in the cell were determined by Western blot using specific antibodies (A). HBV cccDNA in cells was extracted and quantified by a Real-Time PCR method (B), as described previously [22]. The levels of HBeAg in the supernatants were measured by a chemiluminescence immunoassay (C). The levels of HBV DNA in the supernatants were quantified by a Real-Time PCR method (D). Average values of triplicates were calculated and plotted against siRNAs concentrations. � P < 0.05, ��� P < 0.001. The question arose whether the defective HBV infection in the LDLR -/-HepG2 NTCP cells was due to off-target effect associated with CRISPR/Cas9 gene-editing system. To exclude this possibility, we sought to determine if the defective HBV infection in the LDLR-null cells could be restored by ectopic LDLR expression. The stable LDLR -/cell line 3 was used for restoration experiments. The human LDLR-expressing plasmid pCMV6-XL4-hLDLR was transfected into LDLR -/-HepG2 NTCP cells, which were subsequently infected with HBV at 48h post-transfection. The levels of HBcAg and HBV cccDNA in the cell were determined by WB and qPCR, respectively. Results from these experiments showed that the defective HBV infection could be fully restored by ectopic LDLR expression as determined by the levels of HBcAg ( Fig 6A) and HBV cccDNA (Fig 6B).

Enhancement of HBV infection by LDLR overexpression
Down-regulation of LDLR expression caused a significant reduction of HBV infection. Overexpression of LDLR in the parental HepG2 NTCP cells appeared to further enhance HBV infection (Fig 6A and 6B). To confirm if HBV infection could be enhanced by overexpression of LDLR in HepG2 NTCP cells, increasing amounts of the LDLR-expressing vector pCMV6-XL4-hLDLR were transfected into HepG2 NTCP cells, followed by HBV infection at 48h p.t. Interestingly, the levels of HBcAg were significantly increased in proportion to the levels of LDLR expression (Fig 6C). Clearly, HBV infection was well correlated with the levels of LDLR expression. These results demonstrate that the level of LDLR expression determines HBV infection efficiency, consistent with the findings obtained from the above-described down-regulation of LDLR expression (Figs 4 and 5).

Down-regulation of LDLR expression did not affect HBV DNA replication
To exclude the possible effect of LDLR deficiency on HBV DNA replication, an infectious HBV plasmid DNA (pCMV-HBV) was transfected into LDLR -/-HepG2 NTCP cell lines. HBV DNA replication was determined by quantifying the levels of HBcAg, HBV cccDNA, and HBV DNA in the HBV DNA-transfected cells after treatment of DNA samples with the restriction enzyme DpnI (to remove plasmid DNA) and exonucleases I, III, and T5 to degrade HBV rcDNA [36]. The levels of HBcAg (Fig 7A), HBV cccDNA (Fig 7B), and replicated HBV DNA (Fig 7C) remained unchanged between the parental and the LDLR-null HepG2 NTCP cells. These data suggest that the deficiency of LDLR expression did not affect HBV DNA replication.

LDLR serves as an HBV cell attachment receptor via binding to the HBVassociated apoE
The LDLR-blocking monoclonal antibody C7 inhibited HBV infection when added during but not after HBV infection, suggesting its action occurred at a very early step of HBV infection. To define the underlying molecular mechanism of LDLR in the mediation of HBV infection, we carried out an HBV cell attachment assay in the absence and presence of the LDLR monoclonal antibody C7. HBV was incubated with HepG2 NTCP cells for 6 hours with or without C7. The cell-bound HBV DNA was extracted for qPCR quantification upon removal of unbound HBV after extensive washing with PBS. Consistent with its potency in HBV infection, C7 also blocked HBV cell attachment, resulting in about 80% reduction of HBV DNA at 10 μg/mL (Fig 8A). The levels of HBV DNA were also lowered by 70-80% in the LDLR -/-HepG2 NTCP cell lines (Fig 8B). These results suggest that LDLR may function as an HBV attachment receptor. However, HBV entry to cells could not be excluded when HepG2 NTCP cells were used for HBV cell attachment assay. To further confirm the importance of LDLR in HBV attachment, the parental HepG2 cells (without NTCP overexpression) were used for down-regulation of LDLR expression by specific siRNAs, followed by HBV attachment. HepG2 cells were transfected with LDLR-specific siRNAs along with a non-specific siRNA control. As expected, LDLR-specific siRNAs silenced LDLR expression to undetectable levels ( Fig 9A). As a result, HBV cell attachment was significantly reduced by about 75% at 25 nM of siRNA ( Fig 9B). These results demonstrate that LDLR does play an important role in HBV cell attachment.
LDLR is a known apoE-binding receptor like HSPGs [27]. We have previously demonstrated that human apoE is enriched on the HBV envelope and promotes HBV infection [22]. To determine specific interactions between LDLR and apoE, we used a heparin-mediated apoE pull-down assay to examine the blockade of heparin and apoE interaction by LDLR. The heparin-conjugated agarose beads were incubated with apoE in the absence or presence of a purified human LDLR. Interestingly, LDLR efficiently blocked apoE-binding to heparin ( Fig  10A), resulting in a dose-dependent reduction of apoE pull-down as shown by the ratios between heparin-bound and unbound apoE (Fig 10B). These results suggest that LDLR may mediate HBV cell attachment through binding to apoE enriched in the HBV envelope.

Discussion
A number of previous studies have demonstrated that NTCP is the cell surface receptor essential for HBV infection. However, HBV infection in the NTCP-expressing human and murine hepatocytes is very inefficient and relies on the presence of PEG and high HBV inoculum unlike HBV transmission in humans. Neither were NTCP-transgenic mice susceptible to HBV

Role of LDLR in HBV Infection
infection [37,38]. The lack of robust HBV infection in the NTCP-expressing hepatocytes and mice suggests additional cellular factors required for a bona fide HBV propagation. GPC5 was previously shown to promote HBV infection [32]. A more recent study revealed that epidermal growth factor receptor (EGFR) also serves as an HBV entry cofactor through a specific interaction with NTCP [39]. The identification of GPC5 and EGFR as HBV entry factors implies the existence of multiple cell surface receptors/coreceptors involved in HBV infection like HCV [40]. In the present study, we have found that another hepatocyte surface molecule LDLR plays an important role in HBV infection, as demonstrated by several lines of substantial evidence. First, an LDLR-specific monoclonal antibody (C7), which was previously shown to block lipoprotein uptake [41], could potently inhibit HBV infection in the NTCP-expressing HepG2 NTCP cells (Fig 1). C7 blocked HBV infection only when it was added during but not after HBV infection (Fig 3). More importantly, silencing of LDLR expression or knockout of the LDLR gene resulted in a remarkable reduction of HBV infection (Figs 4 and 5). The defective HBV infection in the LDLR-null HepG2 NTCP cells could be fully restored by ectopic expression of LDLR (Fig 6). More significantly, the physiological importance of LDLR in HBV infection was demonstrated in PHHs using LDLR-specific monoclonal antibody C7, which potently blocked HBV infection (Fig 2). In contrast, down-regulation of LDLR expression did not affect HBV DNA replication, as determined by similar levels of HBcAg and HBV cccDNA upon transfection of an infectious HBV DNA into the LDLR-deficient HepG2 NTCP cells (Fig  7). On the other hand, overexpression of LDLR in HepG2 NTCP cells could significantly enhance HBV infection in a dose-dependent manner (Fig 6C). The positive correlation between HBV infection and the levels of LDLR expression demonstrates the importance of LDLR in HBV infection.
LDLR is a single chain transmembrane glycoprotein of 839 amino acids (aa), consisting of a large N-terminal extracellular domain (767aa), transmembrane region (22aa), and the C-terminal cytoplasmic tail (50aa). The N-terminal portion of LDLR contains seven cysteine-rich repeats of 40 residues that constitute the ligand-binding domain. Immediately after the cysteine-rich repeats is a 400-residue region consisting of two epidermal growth factor-like (EGFlike) repeats, a YWTD domain, and a third EGF-like repeat [42]. LDLR plays a critical role in lipid and cholesterol metabolism via its binding to apoB100 on the LDL and apoE on the chylomicron, very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL) particles. In addition to its importance in the uptake of lipoprotein particles, LDLR has been found to serve as an infection-promoting factor for several viruses, including rhinovirus [43], vesicular stomatitis virus (VSV) [44], Rous sarcoma virus [45], and HCV [46]. In the case of rhinovirus, the ligand-binding cysteine-rich repeats of LDLR were found to bind to VP1 [47,48]. The underlying molecular mechanism of the LDLR-mediated VSV cell entry has not been defined. The role of LDLR in HCV infection was probably through an interaction with the host protein apoE that is enriched on the HCV envelope [49]. Circumstantial evidence derived from our current study suggests that LDLR may serve as an attachment receptor for HBV infection. The LDLR-specific monoclonal antibody C7 could efficiently block HBV attachment to HepG2 NTCP cells, resulting in 80% reduction of the cell-bound HBV particles (Fig 8A). Likewise, the knockout of LDLR gene decreased HBV cell attachment by about 70% (Fig 8B). Like HSPGs, LDLR is also a well-known receptor for apoE-binding, which mediates the influx of lipoproteins [50]. We have previously demonstrated that apoE is enriched in HBV envelope and is critical for efficient HBV infection [22]. We speculate that LDLR promotes HBV infection likely through its interaction with the HBV-associated apoE. This possibility is supported by the finding that purified recombinant LDLR was able to block the heparin-mediated apoE pull-down in vitro (Fig 10). ApoE was also previously shown to be enriched on the HCV envelope, mediating HCV cell attachment [23,24,34,51,52]. However, we have not excluded a possible interaction between LDLR and the viral envelope protein HBsAg, which is warranted by future investigations.
Down-regulation of LDLR expression significantly impaired but did not diminish HBV infection, suggesting the involvement of other attachment receptors in HBV infection. Several previous studies suggested that HSPGs serve as HBV attachment receptors. Additionally, other members of the LDLR family may also play a role in HBV infection, including the VLDLR and LDLR-related proteins (LRPs). It was previously shown that the LDLR family members such as LDLR, VLDLR, LRP1, LRP5, and LRP8 can all bind to apoE [50,[53][54][55][56][57]. It will be interesting to determine the importance of other LDLR family members besides LDLR in HBV infection. More significantly, the illustration of the underlying molecular mechanism of the LDLR family members in HBV infection will not only provide new knowledge about the cell surface attachment receptors in HBV infection but also novel targets and/or pathways for discovery and development of antiviral drugs towards the elimination of chronic hepatitis B.

Cell culture
The NTCP-expressing HepG2 cell line (HepG2 NTCP ) and the HBV-producing HepG2 cell line (HepAD38) were described previously [17,58]. They were cultured in DME/F12 medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 U/mL streptomycin (Sigma), 1x MEM non-essential amino acids, and 1x sodium pyruvate, at 37˚C in a 5% CO 2 incubator. PHHs (lot#4405C) were purchased from Lonza and cultured according to the manufacturer's instruction except for the use of Power Primary HEP medium (Takara). HEK293T cells were maintained in DMEM medium containing 10% FBS. All cell culture flasks and plates were coated with 50 μg/mL rat tail collagen type I (Corning) prior to seeding of cells.

Antibodies and reagents
The LDLR-blocking monoclonal antibody C7, which was described previously [41], was produced from a hybridoma obtained from ATCC (CRL-1691) and were purified through affinity chromatography by GenScript (Piscataway, NJ). Mouse anti-LDLR (clone HL1) monoclonal antibody was provided by Jin Ye [49]. A normal mouse IgG was purchased from Santa Cruz Biotechnology. HBcAg-specific mouse monoclonal antibodies (T2221 and C1-5) were purchased from Tokyo Future Style and Santa Cruz Biotechnology, respectively. Goat anti-mouse was from Human β-actin monoclonal antibody (AC15) and protein A and G agarose beads were from Sigma-Aldrich. Mouse anti-NTCP monoclonal antibody was described previously [17]. ApoE-specific monoclonal antibody WuE4 (ATCC) was produced in the lab as described previously [51]. HRP-conjugated goat anti-mouse antibody was from Cell Signaling. Protein assay dye reagent and Clarity Max Western blotting ECL substrate were purchased from Bio-Rad. The LDLR-specific siRNAs and a nonspecific control (NSC) siRNA were synthesized by Dharmacon. Exonucleases I (Exo I), III (Exo III), and T5, as well as Taq 5× master mix were from New England Biolabs. HBeAg chemiluminescence immunoassay (CLIA) kits were purchased from Autobio Diagnostics Co. (Zhengzhou, China). The human LDLR-expressing plasmid pCMV6-XL4/LDLR was obtained from OriGene. The infectious HBV DNA (pCMV-HBV) was described previously [59]. Lipofectamine 3000 and RNAiMax reagents were from Invitrogen.

HBV production and concentration
HepAD38 cells were grown in DME/F12 medium containing 4% FBS and 1% dimethyl sulfoxide (DMSO) in HyperFlasks (Corning). Cell culture supernatants were collected every 6 days and were used for HBV concentration by precipitation with 10% polyethylene glycol (PEG) 8,000 (Hampton Research). The genome copy numbers of HBV DNA were determined by a real-time PCR method.

HBV infection assay
HepG2 NTCP Cells were seeded in 24-well cell culture plates at a density of 1.5×10 5 per well overnight and were infected with HBV at a multiplicity of infection (m.o.i.) of 100 copies of genome equivalent in the present of 4% PEG 8000. After 12 hours infection, unbound HBV was removed by washing with 1x PBS. The HBV-infected cells were incubated with DME/F12 medium containing 3% FBS, 1% DMSO, and 5 μg/mL hydrocortisone (HC) at 37˚C for 4 days. The levels of HBcAg in the infected cells were determined by Western blot. HBV cccDNA in the cell was extracted with the Hirt method and treated with exonucleases prior to quantification by a Real-Time PCR method as described previously [22]. The levels of HBeAg and HBV DNA in the supernatants were quantified by chemiluminescence immunoassay and qPCR, respectively.

Blockade of HBV infection by a LDLR-specific monoclonal antibody
The LDLR-blocking monoclonal antibody (C7) was diluted to varying concentrations (0, 0.4, 2, and 10 μg/mL) with HBV in 4% PEG 8000. HBV with or without C7 was used to infect HepG2 NTCP or PHH cells in 24-well cell culture plates. A normal mouse IgG was used as a negative control. After 12h incubation at 37˚C, the HBV-infected cells were cultured in DME/F12 medium containing 3% FBS, 1%DMSO, and 5 μg/μL hydrocortisone for 4 days. The levels of HBcAg and cccDNA in cells and HBeAg and HBV DNA in supernatants were determined as described above.

SiRNA-mediated silencing of LDLR expression
Varying concentrations (0, 2, 10 and 50 nM) of LDLR-specific siRNAs (siLDLR) or a nonspecific control siRNA (siNSC) were transfected into HepG2 NTCP using lipofectamine RNAiMax reagent. At 48 h post-transfection, cells were infected with HBV as described in HBV infection assay. The levels of HBcAg, cccDNA, HBeAg, and HBV DNA in the cell and supernatant were determined, respectively.

Ectopic expression of LDLR from a DNA vector
HepG2 NTCP or LDLR -/-HepG2 NTCP cells were seeded at 1.5 × 10 5 cells/well in 24-well cell culture plates. The LDLR-expressing plasmid pCMV6-XL4/LDLR DNA was transfected into cells using Lipofectamine 3000 reagent. At 48 h p.t., cells were infected with HBV as described above. The levels of HBcAg and HBV cccDNA were subsequently determined by Western blot and qPCR methods, respectively.

Quantification of HBeAg by chemiluminescence immunoassay
The levels of HBeAg in the cell culture supernatants were determined with a chemiluminescence immunoassay according to manufacturer's instructions, as described previously [22].

Western blot analysis
Cells were lysed in a RIPA buffer. Protein concentrations of cell lysates were determined using protein assay dye reagent. Cell lysates of 25 μg proteins were loaded to 10-18% SDS-PAGE. Upon electrophoresis, proteins in the gel were transferred onto a polyvinylidene difluoride (PVDF) membrane using a semidry blotter (Bio-Rad). Membranes were blocked with 5% nonfat dry milk for 1 h, followed by incubation with primary antibodies specific to HBcAg, LDLR, or β-actin at 4˚C overnight. Proteins were stained with horseradish peroxidase-conjugated secondary antibodies for 1 h and subsequent ECL substrate. Protein bands were visualized and documented with ChemiDoc MP Imaging System (Bio-Rad).

Immunofluorescence assay (IFA)
HBcAg expression in the HBV-infected cells was determined by a previously described IFA with modification [60]. Briefly, HepG2 NTCP cells were seeded at 2 × 10 5 cells/well in 24-well cell culture plates with coverslips coated with collagen. Cells were infected with HBV as described above. Cells were fixed with 4% paraformaldehyde at room temperature for 15 minutes, followed by cell permeabilization with 0.1% Triton X-100 for 5 minutes and blocking with 3% BSA at 4˚C overnight. HBcAg was stained with a HBc-specific monoclonal antibody C1-5 (100-fold dilution) at 4˚C overnight and the secondary goat anti-mouse IgG conjugated with Alera Fluro 594 (2000-fold dilution) at room temperature for 2 h. Coverslips were mounted to glass slides using Prolong Diamond Antifade Mountant with DAPI (Invitrogen). Fluorescence images were taken with Keyence BZ-X800E fluorescent microscope.

HBV cell attachment assay
HepG2, HepG2 NTCP cells, or LDLR -/-HepG2 NTCP cells were incubated with HBV at an m.o.i. of around 50 copies of genome equivalent in DME/F12 medium at 37˚C for 6 h. Unbound HBV was removed by washing with 1xPBS three times. Cell-bound HBV DNA was extracted with a QIAGEN DNA isolation kit, followed by qPCR quantification.

Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 by one-way analysis of variance followed by the Student-Newman-Keuls t-test. Results are shown as means ± standard deviations and all the data were obtained from three independent experiments. P values of �0.05 were considered statistically significant.

S1 Fig. Validation of HBV infection and replication.
HepG2 NTCP cells seeded in 24-well plates were infected with HBV in the presence of 4% PEG. After 12-16h infection at 37˚C, the HBV-infected cells were washed with PBS and incubated with DME/F12 medium containing 3% FBS, 1% DMSO, and 5 μg/mL hydrocortisone (HC), as previously described [17]. At different time points (1 to 9 days) post-infection, cells were lysed with a RIPR buffer. A. Detection of HBcAg by Western blot analysis. The lysates of uninfected and HBV-infected HepG2 NTCP cells were used for protein separation by electrophoresis in a 10% SDS-PAGE gel. HBcAg and β-actin bands were visualized by Western blotting using an HBc-and β-actin-specific antibodies. B. IFA immunostaining of HBcAg in the HBV-infected cells. IFA is described in material and methods. Uninfected HepG2 NTCP cells were used as a negative control. Uninfected and HBV-infected HepG2 NTCP cells at 16h (right after HBV incubation as a measurement of input HBV) and day 5 post-infection were subjected to immunostaining of HBcAg by IFA. The nuclei of cells (Blue) and HBcAg (Red) were stained with DAPI and anti-HBc (C1-5)/Alexa Fluor 594 goat anti-mouse IgG, respectively. Fluorescence images were taken using the Nikon S plan fluor 40x objective and either an exposure of 1/3s or 1/2s for DAPI and HBcAg, respectively. Scale bars at the bottom right corner indicate 100 μm. (TIF)

S2 Fig. Immunostaining of HBcAg in the HBV-infected HepG2 NTCP cells with or without LDLR silencing.
HepG2 NTCP cells were transfected with 50 nM of LDLR-specific siRNAs (siLDLR) or a non-specific control siRNA (siNSC) using RNAiMax (Invitrogen). At 48 hours upon siRNA transfection, cells were infected with HBV in the presence of 4% PEG at 37˚C for 16 hrs. Uninfected HepG2 NTCP (negative control) and HBV-infected cells right after 16-h incubation (input virus control) or at day 5 post-infection were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and stained for HBcAg by IFA. Cell nuclei were stained with DAPI (Blue) and HBcAg was stained with an anti-HBc (C1-5) and the secondary Alexa Fluor 594 goat anti-mouse IgG (red). Fluorescence images were taken using the Nikon S plan fluor 40x objective and either an exposure of 1/3s or 1/2s for DAPI and HBcAg, respectively. Scale bars at the bottom right corner indicate 100 μm. (TIF)